Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations  by Jobes, David R. et al.
INCREASED ACCURACY AND 
PRECISION OF HEPARIN 
AND PROTAMINE DOSING 
REDUCES BLOOD LOSS AND 
TRANSFUSION IN PATIENTS 
UNDERGOING PRIMARY 
CARDIAC OPERATIONS 
Individual aspects of heparin or protamine dosing have been better controlled 
9 than previously as useful tests have become available. Although many variables 
including drug potency, drug source, and individual patient response have 
been separately identified, there has not been an attempt to integrate them into 
a single management strategy. This study was undertaken to learn whether 
more precise control of drug variables and patient response would affect blood 
loss and transfusion requirements. Adult patients having primary cardiac 
operations were prospectively randomized into two groups. A control group 
received heparin and protamine by conventional methods. The test group 
received heparin and protamine according to in vitro predictive tests integrat- 
ing drugs, tests, and patient response. Supplemental protamine was given, in 
this group only if heparin was specifically found by testing. Anticoagulation i  
all patients was maintained at an activated coagulation time greater than 400 
seconds, and any other treatment for bleeding was at the discretion of the 
clinical team caring for the patients. Testing and treatment for both groups 
followed routine practice after patient arrival in the intensive care unit. Test 
patients received slightly more heparin and a markedly lower dose of prota- 
mine than the control patients. Testing identified patients with decreased 
heparin sensitivity (preoperative h parin therapy) and correctly predicted the 
effective heparin dose. Supplemental protamine was given twice as often to 
control patients and frequently when no heparin was detectable (retrospective- 
ly). Test patients exhibited less 24-hour chest tube drainage (671 ml versus 
1298 mi) and fewer patients received transfusion (9/22 versus 18/24) with fewer 
donor exposures (22/22 versus 101/24). The management s rategy used for 
heparin and protamine added accuracy and precision, which was associated 
with improved hemostasis. Although the observation is valid, the mechanism 
or mechanisms are not completely clear. Nevertheless, it is reasonable toapply 
basic pharmacologic principles and establishment of consistent, predictable 
protocols that are beneficial. It is against his background that the efficacy of 
additional drugs or equipment should be assessed. It is quite possible that only 
marginal if any improvement in hemostasis may be found in patients having 
primary, uncomplicated cardiac operation with the addition of more costly 
drugs or equipment. (J THORAC CARDIOVASC SURG 1995;110:36-45) 
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T he dose of heparin required to inhibit coagula- tion for cardiopulmonary b pass (CPB) was ini- 
tially chosen on an empiric basis with supplementa- 
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tion based on its half-life in the circulation. Prota- 
mine was given in proportion to heparin adminis- 
tered without knowledge of the actual heparin level 
at the time of protamine administration. Bull and 
associates 1 in 1975 demonstrated significant patient- 
to-patient variability in dose response and duration 
of heparin effect. They recommended individualized 
heparin and protamine dosing with use of a dose- 
response plot based on the whole bleod activated 
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coagulation time (ACT). 2 The goals were (1) to 
provide consistently adequate anticoagulation and 
(2) to administer a dose of protamine that would be 
more closely related to the heparin present at the 
termination of CPB. Since 1975 many investigators 
have used this and other methods to more precisely 
control heparin and protamine dosing. 3-16 
This management strategy reduced drug doses 
and was frequently associated with reduction of 
blood loss or transfusion requirements, or both. The 
lack of consistent findings of decreased bleeding or 
transfusion, or both, with lower drug doses may 
relate to differences in study design, patient popu- 
lations, reporting terminology, doses, source and 
potency variability of drugs used. and test methods. 
However, the intuitive appeal of more precise treat- 
ment, the desire for improvements in hemostasis 
with associated reductions in transfusion, and the 
increasingly recognized undesirable ffects of excess 
drugs prompted another investigation. A system for 
maintaining consistency of drugs and for individual- 
1zing patient dosing for both heparin and protamine 
that uses a matched injectable drug and in vitro 
dose-response assay has been introduced (RxDx 
System, International Technidyne Corporation. Edi- 
son. N.J.), thus amplifying the recommendations 
made by'Bull and associates. 2 It was the goal of this 
study to determine whether ,an attempt o control 
drug variables maximally would be associated with 
less bleeding and fewer transfusion requirements in
adult patients undergoing primary cardiac operation 
with CPB. 
Methods 
Approval of the protocol was obtained from the Uni- 
versity of Pennsylvania human studies committee. Con- 
secutive patients undergoing primary elective cardiac op- 
eration were candidates when the planned procedures 
included either coronary artery bypass grafting, mitral 
valve replacement, aortic valve replacement, or any com- 
bination of the three. Patients who had previous cardiac 
operation, a history of bleeding disorder, or evidence of 
other organ dysfunction were excluded. Patients~receiving 
preoperative hepari n in whom the ACT exceeded 200 
seconds (after sternotomy) were excluded. All three staff 
cardiac surgeons and six cardiac anesthesiologists agreed 
to the protocol before the study began, cared for patients 
in random combination, and were not directly informed of 
an individual patient's tudy status at the time of opera- 
tion. Formal blinding was not attempted; however, none 
of the physicians who directed care of the Study patients 
were members of the investigative t am. The investigators 
who performed the tests did not participate in the deci- 
sions for treatment. Other than ACT findings, test results 
used for study purposes were not disclosed to the clini- 
cians. 
On arrival in the operating room, patients were 
screened for candidacy for the study. Once enrolled, 
patients were randomly assigned to the control group or 
test group by medical record number. The patient's 
preoperative hemoglobin and hematocrit values, platelet 
count, activated partial thromboplastin me, prothrombin 
time, and preoperative medications were recorded. The 
9 patient's weight and height were used to determine intra- 
vascular volume from a blood volume nomogram. 17
Whole blood ACT was determined induplicate with use 
of a Hemochron 801 dual-chambered timer with a 300- 
second prewarming feature. A Hemochron CA510 tube 
(International Technidyne) (containing 12 mg of Celite 
diatomaceous earth. Johns Manville Corp., Denver. 
Colo.) was placed in the timer test well for 300 seconds to 
warm the glass tube and test well to 37 ~ C. Ten milliliters 
of whole blood was aspirated from the arterial ine before 
a 4 ml sample for testing was drawn. A 2 ml sample was 
added to the tube, the timer started, the tube shaken 
vigorously until the diatomaceous earth was completely 
dispersed throughout the blood sample (approximately 3 
to 5 seconds), and then the tube was placed in the reaction 
well. 
Anesthetic management. All current cardiovascular 
medications were maintained until patient ransport to 
the operating room (including heparin) at which time they 
were discontinued. All patients were premedicated with 
morphine sulfate and scopolamine, and all received a 
16-gauge peripheral intravenous catheter, 20-gauge radial 
artery catheter, and pulmonary artery catheter via the 
right internal jugular vein before induction of anesthesia. 
A combination ofhigh-dose fentanyl, isoflurane or enflu- 
rane, and nondepolarizing muscle relaxant was used to 
produce anesthesia. 
Test group. In the test group, heparin and protamine 
requirements were based on analysis of individual 
patient response in vitro to heparin and protamine with 
use of an integrated rug/test system The components 
of the system include heparin and protamine for admin- 
istration to the patient and test tubes containing the 
same drugs for determining the heparin and protamine 
response times. 
The heparin response test (HRT) was performed 
simultaneously in duplicate with a preheparin, postster- 
notomy reference ACT. Two milliliters of whole blood 
was added to the heparin response test test tube 
containing 12 mg diatomaceous earth and 6 units of 
heparin from the same lot to be administered to the 
patient, (resulting in a concentration f 3 units per ml). 
The test was then done in the same way as the ACT. 
The prolongation of the ACT reflects individual patient 
response to heparin (heparin response test), which was 
used with the patients' estimated blood volume (EBV) 
to calculate a heparin dose to produce a target ACT. 
Product information suggested an expected standard 
deviation of +82 seconds for a concentration f 3 units 
heparin per milliliter of blood. The projected ACT 
chosen was 482 seconds, thus we attempted to ensure a 
value greater than 400 seconds and avoid supplemental 
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doses and delays in beginning CPB. Equation 1 was 
used to calculate the heparin dose in units: 
3(480 - ACT) 
Heparin dose = (HRT - ACT) x EBV (1) 
The protamine response test (PRT) was used to deter- 
mine the protamine dose. A 2 ml heparinized whole blood 
sample was added to the PRT test tube containing 12 mg 
diatomaceous earth and 0.04 mg protamine sulfate from 
the same lot of protamine to be administered to the 
patient. The test was then done in the same way as the 
ACT. The PRT was done within 10 minutes of the end of 
CPB simultaneously with an ACT (status ACT). The 
reduction of the ACT reflects individual patient response 
to protamine (0.02 mg/ml), which is used with the esti- 
mated blood volume (EBV) to calculate a protamine 
dose. The dose used in the study.reflects he amount of 
protamine required to return the ACT to the poststernot- 
omy ACT reference value. Equation 2 was used to calcu- 
late the protamine dose in milligrams: 
0.02(ACTstatus - ACTbaseline 
Protamine dose = • EBV 
(ACTstatus - PRT) 
(2) 
The protamine was administered after the cessation of 
CPB over 5 to 10 minutes. Five minutes later, an ACT, 
thrombin time (TT), and heparin-neutralized thrombin 
time (HNTF) were obtained (International Technidyne). 
The TT test contains lyophilized thrombin and the HNTT 
test contains lyophilized thrombin plus 0.032 mg prot- 
amine sulfate. Heparin levels greater than 0.05 unit/ml 
will significantly prolong the TT but result in a normal 
HNTT. Thus the difference between them (A) when 
measured simultaneously can be used as a sensitive and 
specific indicator of residual heparin. One milliliter of 
distilled water was used to reconstitute the reagents at 
room temperature. Tubes were then prewarmed, 1 ml 
blood added, and the timer started. Thorough mixing of 
the liquid reagent and blood is accomplished readily by 
gently tilting the tube four times, and the tube is placed in 
the reaction well. Vigorous agitation must be avoided or 
foaming of the reagent before or after the blood is added 
will invalidate test results. 
Subsequent protamine in the test group was adminis- 
tered only if the ATT/HNTT indicated residual heparin 
(ATT/HNTT >12 seconds). When heparin was detected, 
10 mg of protamine was given and the tests repeated. This 
process continued until no heparin was detectable. When 
no heparin was detected, treatment for microvascular 
bleeding in the operating room was at the discretion of the 
surgeon or anesthesiologist, who could use any modality 
except protamine. Protocol restriction ended after arrival 
in the surgical intensive care unit and any treatment 
(including protamine) or routine testing was at the discre- 
tion of the surgical staff who were not involved in the 
study. 
Control group. The control group represented institu- 
tional practice. The initial dose of porcine-derived hepa- 
rin was 300 units/kg and ACT was determined 5 minutes 
after the bolus dose. I f  the ACT exceeded 400 seconds, 
the patient was placed on CPB. If the ACT was less than 
400 seconds, 5000 units supplemental heparin was admin- 
istered and the ACT repeated until the result exceeded 
400 seconds. 
The initial protamine dose was 1.0 mg protamine per 
100 units heparin infused. This was based on the tota l  
number of units of heparin given to the patient hrough- 
out operation, excluding the 5000 units of heparin in the 
pump prime. The protamine was administered after the 
cessation of CPB over 5 to 10 minutes. Five minutes later 
an ACT was obtained. Additional protamine or any other 
treatment for bleeding was given at the discretion of the 
Cardiac surgeon or the anesthesiologist, using indepen- 
dent judgment with or without regarding the ACT results. 
A heparin response test was obtained before heparin 
administration~ a PRT before protamine administration, 
and ATT/HNTT after protamine administration. These 
values were not available to the clinicians but were saved 
for later comparison. 
Conditions common to all patients. All patients re- 
ceived 5000 units of porcine-derived heparin in a pump 
prime Of 2.2 L of balanced electrolyte solution. Through- 
out the study all patients in both groups received heparin 
and protamine that were from the same lot and concen- 
tration. In both groups, 5 minutes after the beginning of 
CPB and every 30 minutes thereafter the ACT was 
measured. Additional heparin was administered only if 
the ACT dropped below 400 seconds. All tests were done 
in duplicate and the average values used for data analysis. 
Blood scavenged before and after CPB and residual pump 
contents were filtered and washed. The resultant packed 
red blood cells suspended in normal saline solution were 
returned to the patient intravenously. No attempt was 
made to measure blood loss in the operating room. Blood 
collected from the chest tubes during wound closure was 
included as part of the total postoperative blood loss and 
measured by volume. Transfusions, additional drugs, or 
any other measures to treat bleeding in the operating 
room and surgical intensive care unit were chosen at the 
discretion of the anesthesia nd surgery staff by routine 
means of assessment and transfusion guidelines. 
Data collected. All drug doses and test results were 
recorded along with the time administered. Any intraop- 
erative blood product ransfusions were noted, as well as 
any medications to treat bleeding. Hematologic profile 
(hemoglobin and hematocrit values, platelet count, pro- 
thrombin time, and activated partial thromboplastin 
time), volume of mediastinal b ood drainage, transfusions, 
and medications were recorded uring the first 24-hour 
postoperative period and were obtained from the inten- 
sive care unit nursing records: Any patient with incom- 
plete data resulting from return to the operating room 
after operation, death in the first 24 hours, or deviations 
from protocol was removed from the study. 
Data were analyzed by Student's t test, analysis of 
variance (with Sheffe's test), Fisher's exact test, X z test, 
and F test where appropriate. 
Results 
Demographics.  Fifty-two patients were entered 
into the study and six were excluded from data 
analysis. Three pat ients were excluded from the test 
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Table I. Demographic data 
Control Test 
(n = 24) (n - 22) p Values 
Male/female 19/5 14/8 0.13 
Age (yr) 65 ~ 10 63 z 12 0.32 
Weight (kg) 78 _+ 9 82 z 17 0.14 
Height (cm) 170 _+ 7 169 z 10 0.47 
CPB time (min) 79 _+ 27 82 _~ 24 0.41 
Surgical procedure 
CABG, vein only 5 5 0.28 
CABG, vein/IMA 16 11 0.24 
A valve 2 2 0.39 
M valve 1 2 0.50 
A valve, CABG 0 1 0.50 
M valve, CABG 0 1 0.50 
Preoperative drug therapy 
Heparin 10 11 0.20 
Aspirin 12 9 0.19 
Data given as mean plus or minus standard.deviation where appropriate. 
p Values determined by t test for unpaired ata and Fisher's exact est. 
CABG, Coronary artery bypass grafting; IMA, internal mammary artery;A, 
aortic; M, mitral. 
group because of dose calculation errors and use of 
an incorrect lot of heparin. Three patients were 
excluded from the control group: one patient was 
returned to the operating room because of excessive 
bleeding for which a specific site was found and 
ligated, and a second patient was returned to the 
operating room after operation for treatment of an 
acute ischemic episode and subsequently died. The 
third patient was excluded because of a drug dose 
error. Drug dose errors were clinically unimportant 
but were deviations from protocol and were consid- 
ered grounds for exclusion. 
No patient previously receiving heparin had an 
ACT greater than 200 seconds. The results of the 
randomization process and the patient characteris- 
tics are illustrated in Table I. There were no differ- 
ences between control and test groups for" the 
features listed. Both groups were also similar with 
regard to laboratory results for standard coagulation 
tests and hemoglobin concentration (Table II). 
There was a slightly higher hemoglobin value in the 
test group 12 hours after admission to the surgical 
intensive care unit but there were no differences at 
the time of discharge from the hospital. All patients 
for whom data were collected were discharged from 
the hospital to ,their homes. Postoperative compli- 
cations were arrhythmias (heart block necessitating 
pacemaker insertion: two in the test group; one in 
the control group), transient acute renal failure (one 
in the test group), and wound infection (one in each 
group). 
Table II. Laboratory results 
Control Test 
group group p Values 
Before operation 
APTT (sec) 34.2 _+ 11.1 38.0 z 15.8 0.95 
PT (sec) 11.8 z 1.3 11.4 z 0.7 0.16 
Platelets (103 mm 3) 271 z 110 282 _~ 70.6 0.35 
Hemoglobin (gm/dl) 13.3 - 1.3 12.9 _ 1.5 0.14 
SICU, on arrival 
APTT (sec) 36.2 _+ 7.5 38.7 + 9.2 0.17 
PT (sec) 14.3 z 1.3 13.7 z 1.6 0.12 
Platelets (103 mm 3) 186 _+ 93.8 167 z 55.8 0.07 
Hemoglobin (gm/dl) 9.5 _+ 1.2 9.9 z 1.4 0.29 
SICU, 12 hours 
APTT (sec) 32.7 z 3.5 33.0 § 6.7 0.45 
PT (sec) 13.4 z 1.5 13.2 _+ 1.4 0.31 
Platelets (103 mm 3) 158 z 57.6 149 __ 42.8 0.29 
Hemoglobin (gm/dl) 9.3 ~ 1.1 10.0 z 1.3 0.02 
Discharge from hospital 
Hemoglobin (gm/dl) 9.9 ~ 0.7 11.1 T 4.4 0.27 
Data given as mean plus or minus tandard eviation.p Values determined 
by t test for unpaired ata. APTT. Activated partial thromboplastin time: 
PT. prothrombin time; SICU, surgical intensive care unit. 
Response to heparin. Heparin sensitivity may be 
described by calculating the prolongation of ACT 
per unit of heparin per milliliter of blood (seconds 
per unit per milliliter). Fig. 1 shows in vivo heparin 
sensitivity compared between groups and in patients 
with and without prior heparin therapy. There was 
no difference between test and control groups. The 
patients previously receiving heparin demonstrated 
lower sensitivity but with a high degree of correla- 
tion between in vitro and in vivo results. Patients not 
previously receiving heparin demonstrated consis- 
tently higher than expected in vivo values with more 
variability after systemic heparin administration. 
Doses of heparin and protamine. Drug dose re- 
sults are shown in Table III. Patients in the test 
group received more heparin than those in  the 
control group. Heparin dose was more variable in 
the test group; however, the average ACT after the 
initial dose was the same in both groups. Two 
patients in the control group did not reach the 
required 400-second ACT after a bolus of 300 
units/kg and were given additional heparin before 
CPB. All patients in the test group achieved an ACT 
greater than 400 seconds after the bolus dose. 
Additional heparin (ACT <400 seconds) was nec- 
essary for three patients in each group during CPB. 
Three of these patients had previously been receiv- 
ing heparin and three had not. 
Patients in the control group received more pro- 
tamine as an initial dose and as a total dose than 
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No Preop. I-Ieparin 
r=0.5 
*Difference between Hel~'in vs No FIeparin; unpaired t-test (p~0.05) 
~:Difference between In Vitro vs In Vivo; paired t-test (p<0.05) 
[ ]  In Vitro Sensitivity 
9 In Vivo Sensitivity 
Fig. 1. Sensitivity to heparin in vitro (3 units per milliliter blood in ACT test ube) compared 
with in vivo (postbolus intravenous heparin ACT calculated as ACT seconds per unit per 
milliliter using nomogram for estimated blood volume). Two groups of patients were identified 
~from the 46 study patients: 21 who were receiving heparin intravenously (Preop. Heparin) 
before coming to operating room and 25 who were not (No Preop. Heparin). 
Table I lL Heparin and protamine dosages 
p Values p Values 
Control group Test group for means for variance 
Total heparin dosage (units) 24951 + 2995 29953 z 8804 <0.01 
Postheparin ACT (sec) 560 -+ 142 557 ~ 119 0.46 
Initial protamine dose (mg) 249 4- 30 136 z 33 <0.01 
Additional protamine (No. of patients) 13 7 0.16 
Average protamine added (mg) 55 • 21 30 • 14 <0.01 






Data given as mean plus or minus tandard eviation, p Values determined by t test for unpaired ata for drug dose comparison. Fisher's exact est for patient 
distribution, and F test for variance. 
patients in the test group. Supplemental protamine 
was given twice as often and in nearly twice the 
quantity in the control group than in the test group. 
Thirteen patients received supplemental protamine 
in the control group (nine in the operating room and 
four additional patients in the surgical intensive care 
unit). Patients in the test group were given no 
supplemental protamine after complete neutraliza- 
tion in the operating room. Three patients were 
given supplemental protamine as indicated by ATT/ 
HNTF on arrival in the surgical intensive care unit. 
The protocol ended at this point; however, no 
patient in the test group was given additional prot- 
amine during the remainder of the surgical intensive 
care unit stay. No treatments other than protamine 
and blood products were used in any study patient. 
Blood loss and  transfusion (Table IV). Oper- 
ating room blood loss is partly reflected in the 
quantity of washed cells from intraoperative scav- 
enging and residual pump blood, which was the 
same in both groups. Allogeneic packed blood cells 
were administered with equal frequency in the op- 
erating room to patients in both groups (control, 5; 
test, 4). Chest tube drainage was greatest in the first 
4 hours in both groups and greater in the control 
group during the first 12 hours (Fig. 2). Total loss 
was also greater for the entire 24-hour period in the 
control group. Autotransfusion of chest tube drain- 
age was practiced similarly in both groups with more 
patients receiving a greater volume in the control 
group. Twelve patients in the control group and five 
in the test group received packed red blood cells in 
the surgical intensive care unit. Five patients were 
given platelets and five patients were given fresh 
frozen plasma in the control group whereas no 
patient in the test group received either of these 
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Table IV. Blood loss and transfusion 
Control Test 
group group p 
(N = 24) (N = 22) Values 
Mediastinal blood loss (ml) 
12 hr 1068 _+ 645 495 _+ 257 <0.01 
24 hr 1298 + 747 671 + 333 0.01 
Allogeneic transfusion 
Donor units used 101 22 0.02 
Patients receiving 18 9 0.02 
transfusion 
No. of patients who received 
Red blood cells 17 9 0.01 
Fresh frozen plasma 5 0 0.03 
Platelets 5 0 0.03 
Autotransfusion 
Intraoperative washed 2.6 __ 0.8 2.8 z 1.2 0.63 
cells (units) 
Chest tube drainage 799 -- 455 425 = 147 <0.01 
transfused (ml) 
Data given as mean plus or minus standard eviation where appropri- 
ate. p Values determined by ~ test for unpaired ata and Fisher's exact 
test .  
products. Forty percent of the patients in the test 
group received allogeneic transfusion i contrast to 
75% in the control group. The total number of 
donor exposures was notably greater in the control 
group. 
Discussion 
Patient selection and study design. The patients 
in this study underwent ypical primary cardiac 
surgical procedures and those receiving aspirin and 
heparin were included. The average volume of 
postoperative blood loss in the control group (1298 
--- 747 ml) is quite similar to 1016 + 25 ml, the 
estimated average of total blood lost by 540 patients 
undergoing primary coronary artery bypass grafting 
from 18 institutions in the United States. is Formal 
blinding was not done but given that the mainte- 
nance minimum heparin effect was the same in both 
groups the heparin management was unlikely to be 
biased. Bias affecting therapy of microvascular 
bleeding is more likely , because the clinicians could 
use any modality except protamine for the test 
patients in the operating room and were thus aware 
of the grouping. However, the existing clinical prej- 
udice was for more aggressive treatment ofobserved 
microvascular bleeding, yet no patient in the test 
group received platelets or fresh frozen plasma. 
Similarly, such treatment (including protamine), if
efficacious, should haye favored less bleeding in the 
control group. In addition, treatment of the test 
600 
t • 
9 T,,t II , [] co.t~ol 200-  
I I I l I 
0 4 8 12 16 20 24 
Hours 
*ANOVA, 1~-0.05 
Fig. 2. Chest ube drainage as measured in4-hour inter- 
vals in the surgical intensive Care unit for first 24 hours 
after operation. Time 0 represents accumulation begun in 
operating room during closure of chest incision until 
arrival in surgical intensive care unit. No patient exhibited 
active bleeding after recording period. ANOVA, Analysis 
of variance. 
group in the surgical intensive care unit after the 
end of the protocol was decided by surgical staff who 
were not involved in the study and often not present 
during the intraoperative phase. 
In vitro predictability of in vivo drug effect: 
heparin. All patients received adequate anticoagu- 
lation (ACT >400 seconds) with the initial dose in 
the test group. The postbolus heparin effect was 
consistently more than predicted by in vitro results 
in patients not previously receiving heparin. We do 
not have an explanation for this observation, which 
suggests that patients not previously receiving hep- 
arin generate more anticoagulant effect after a bolus 
of heparin than takes place in circulating blood 
alone as measured by the ACT in vitro. 
Conversely, patients previously receiving heparin 
are less sensitive to doses administered before CPB, 
an observation i patients undergoing cardiac oper- 
ation that has been made by others. 19-21 An expla- 
nation may lie in previous reports of decreased 
levels of antithrombin III associated with prolonged 
heparin therapy. 22'23 Besides diminished heparin 
sensitivity, it is interesting to note that there was an 
extremely high correlation between in vitro and in 
vivo heparin effect as measured by the ACT in 
patients previously receiving heparin. This observa- 
tion suggests that the response to heparin in these 
patients is limited to an effect in circulating blood 
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only. The in vitro response to heparin (heparin 
response test) was sufficiently reliable in predicting 
the in vivo response and resulted in all patients 
receiving adequate anticoagulation with the initial 
dose of heparin. Patients with diminishing heparin 
effect caused by discontinuation of preoperative 
heparin therapy should have a heparin response test 
done after sternotomy and immediately before hep- 
arin for administration CPB. This group demon- 
strated the highest accuracy of the in vitro test. 
In vitro predictability of in vivo drug effect: 
protamine. The calculation for initial protamine 
dose in the test group used the preheparin ACT 
value when it was below the upper limit of the 
normal range (122 2 10 second), and if the dose was 
exact it would leave no residual heparin nor an 
excess of protamine. There was therefore no at- 
tempt o provide xcess protamine for prevention of 
heparin rebound to assess the accuracy of the 
method. Four of 22 patients had measurable hepa- 
rin effect (by ATTAtNTT) after the initial dose of 
protamine. The incremental dministration f small 
doses of protamine to these four patients averaged 
30 mg (range 20 to 50 mg) to reach complete 
neutralization. Considering the inherent variations 
in estimating blood volume and the measurements 
of ACT, the calculations were surprisingly accu- 
rate. 
Doses of heparin and protamine. Close matching 
of heparin dose to variable individual patient re- 
sponse is readily evident from the wide range of 
initial doses in the test versus control groups (14,500 
to 50,000 versus 19,000 to 29,000 units) but with a 
shorter ange of response (postbolus ACT 447 to 
894 seconds versus 325 to >1000 seconds). There 
are several explanations for the slightly increased 
total dosage of heparin seen in the test group. More 
initial heparin was given in the test group partly 
because the target ime was set t standard eviation 
higher than 400 seconds to avoid values less than the 
minimum needed to begin CPB. Lower total hepa- 
rin dosage would have been likely in more sensitive 
patients if the heparin in the pump prime had been 
eliminated. Also the in vitro prediction was unex- 
pectedly in excess of the in vivo result. If a projected 
ACT of 400 seconds was consistently achieved and 
maintained, a lower total heparin dosage (and 
therefore protamine dose) would be likely because 
the average ACT at the end of CPB was 521 
seconds. It would be expected that with longer CPB, 
the average heparin used would be the same for 
empiric and test-guided dosing because of mainte- 
nance of the same minimum effect (in this study an 
ACT of 400 seconds). However, a test-guided ap- 
proach would clearly favor reduced heparin for CPB 
of shorter duration in more sensitive patients. The 
result would be a lower dose of heparin and also of 
protamine while the desired heparin effect was 
achieved and maintained.* It is unlikely that the 
higher dosage of heparin in the test group accounts 
for the difference in blood loss. The dosages and 
ACT Values for both groups are well within the 
range reported to be adequate. Both groups howed 
the same average ACT and PRT at the end of CPB, 
and the same number of patients in both groups 
required supplemental heparin for maintenance ef- 
fect. The contribution of the method of heparin 
dosing in this study to the outcome is not clear. 
The initial and total dosages of protamine admin- 
istered were markedly different between the groups. 
Previous reports have attributed reduced blood loss 
or transfusion to lower protamine dosages but have 
not identified a mechanism. A number of studies 
demonstrate hat heparin and protamine adversely 
affect platelet number and function. Ellison, Ed- 
munds, and Coleman 24 found that these drugs in 
combination i hibited adenosine diphosphate and 
epinephrine-induced platelet aggregation i  normal 
volunteer subjects. The inhibition was observed only 
when protamine was present with heparin in neu- 
tralizing and excess amounts. No inhibition was seen 
with heparin alone, protamine alone, or when hep- 
arin was underneutralized. One of the lowest doses 
of protamine associated with significantly ess bleed- 
ing was accompanied bya higher platelet count after 
protamine administration than that in a Control 
group. 2s The administration of protamine in the 
presence of heparin is associated with an inflamma- 
tory type of response with a wide range of effects 
associated with complement and neutrophil activa- 
tion.26, 27 An acute decrease in the number of circu- 
lating platelets is observed after protamine admin- 
istration, which is associated with an acute rise in 
complement levels. 26 A similar course is followed by 
neutrophils. Neutrophil activation is thought o re- 
sult from action by complement resulting in neutro- 
phil-endothelial dhesion and sequestration. 27 A 
similar mechanism ay be affecting platelets and 
*Experience after the study with RxDx System management and 
no heparin in the pump prime showed an average reduction of 
approximately 7000 units of heparin and 20 mg of protamine. 
Fifteen patients matched to the test patients for procedure 
and CPB time had an average total heparin dose of 21,967 +_ 
8698 units and total protamine dose of 125 _+ 39 mg. 
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the possibility of a dose-related effect (protamine or 
heparin-protamine complex) on both platelets and 
neutrophils should be considered for additional 
investigation. 
Concern for inadequate heparin neutralization 
and heparin rebound prompts most clinicians to 
administer a large initial dose of protamine in the 
belief that they are preventing bleeding without 
causing harm. In addition, they frequently judge 
heparin effect by visual assessmen t of coagulation at 
the surgical site or by the ACT, or by both methods. 
More protamine is given on the basis of these two 
nonspecific and insensitive criteria. The control 
group in this study received a commonly used dose 
of protamine that was intended to provide complete 
neutralization and some degree of excess to prevent 
heparin rebound. When this dose was judged inad- 
equate by the aforementioned criteria in the control 
group, additional protamine was given. Despite this 
liberal approach, evidence (ATT/HNTT) of heparin 
effect was found in two patients in the operating 
room and one additional patient on arrival in the 
surgical intensive care unit. Fourteen supplemental 
doses of protamine were given to patients in the 
control group, 13 of these when there was no 
heparin detectable by ATT/HNTT. The method 
used in the control group does not guarantee neu- 
tralization or protection against he reappearance of 
heparin but contributes to the larger doses of prot- 
amine likely to be  responsible for more bleeding, 
not less. The lowest effective dose of protamine is 
associated with improved hemostasis, decreased 
blood loss, and decreased transfusion requirements 
and is a worthwhile goal. The only way to achieve 
that goal is to individualize the dose by test specific 
methods (see following section). 
Monitoring adequacy of heparin neutralization. 
The ability to confidently choose an accurate dose of 
protamine is only possible by assessment of the 
amount of neutralizable heparin in the circulation. 
Similarly, the ability to limit subsequent doses of 
protamine requires a sensitive and specific test for 
the presence of hepafin. The partial thromboplastin 
time may be sensitive to heparin in other settings but 
is frequently abnormal after CPB for reasons other 
than heparin, is not specific for heparin, and is not 
useful. An ACT/modified with serial protamine can 
be specific and quantitative for heparin and can be 
done by a manual or automated protamine titration. 
However, the ACT itself is relatively insensitive to 
heparin in quantities thought o contribute to post- 
operative bleeding and is similarly not useful. Alter- 
natively, the whole blood TT is sensitive to heparin 
and its modification by the addition of protamine 
(HNTT) renders it specific for heparin. It is nearly 
as simple to use' as the ACT and in addition can 
detect significant fibrinogen abnormalities while 
maintaining the ability to detect heparin. 
Blood loss and transfusion requirements. Blood 
loss and transfusion in cardiac operations have 
received increasing emphasis, and methods to re- 
duce both have been the subject of numerous re- 
ports. The goal is the least blood loss and therefore 
presumably the least transfusion consistent with 
preserving the benefits of operation at the lowest 
cost. Drugs (aprotinin, 1-deamino-8-D-arginine va-
sopressin [DDAVP], E-aminocaproic acid, tranex- 
amic acid), techniques (autologous fresh blood, 
platelet pheresis, allogeneic fresh blood, dilutional 
anemia, lower transfusion trigger), equipment (hep- 
arin-bonded circuits, membrane oxygenators, hemo- 
filtration), tests (ACT, protamine titration, throm- 
boelastography, Sonoclot [Sienco, Inc., Morrison, 
Colo.]), and perhaps other manipulations have been 
tried. Differences in the indices measured and re- 
porting formats make comparisons of efficacy be- 
tween reports difficult. However, one of the most 
accurately measurable and consistently reported as- 
sessments is the 24-hour chest tube blood loss. 
Admittedly it ignores intraoperative losses, which 
are seldom directly measured or reported and are 
more under direct technical control. However, chest 
tube collections probably more accurately reflect 
physiologic effects of CPB management. The lowest 
reported measured losses for adult patients having 
primary cardiac operation are approximately 400 to 
600 ml. The lowest values reported have been 
generally achieved with the use of aprotinin but 
other measures have been as effective. For example, 
0vrum and associates 2  were able to avoid alloge- 
neic transfusion in 98.6% of 500 patients having 
primary coronary artery bypass grafting whose aver- 
age chest tube blood loss was 643 _+ 354 ml. The 
only apparent difference between the study of 
~vrum and associates 2 and other reports was ces- 
sation of aspirin before operation and reinfusion of 
autologous blood drawn just before CPB, that is, no 
additional drugs or new technique was used to 
intentionally improve hemostasis. Boldt and col- 
leagues 29 found no difference in chest tube loss 
(approximately 400 ml) or transfusion requirement 
with or without aprotinin if normothermic bypass 
was used. A more appropriate comparison of our 
current study can be made with a recent report by 
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Table V. Data from two trials to reduce bleeding in 
primary cardiac operations in adults 
Control Treatment 
Trial 1 Trial 2 Trial 1 Trial 2 
Age (yr) 65 64 63 62 
Weight (kg) 78 82 82 83 
CPB time (min) 78 98 82 99 
Preop. Hgb (gm/dl) 13.3 13.5 12.9 13.7 
Hgb decrement (gm/dl) 3.4 2.8 1.8 2.7 
Chest ube drainage (ml) 1298 1503 671 855 
Donor exposure (units/patient) 4.2 5.7 1.0 2.2 
RBC (units/patient) 1.9 2.1 1.0 1.1 
Platelets (units/patient) 1.5 1.9 0 0.8 
FFP (units/patient) 1.4 0.7 0 0.3 
Cryoprecipitate (units/patient) 0 0.9 0 0. 
Trial 1: current study using RxDx System; Trial 2: aprotinin as reported by 
Lemmer and associates. 3~Preop., Preoperative; Hgb, hemoglobin; RBC, 
red blood cells; FFP, fresh frozen plasma. 
Lemmer and associates 3~ of patients who received 
aprotinin or placebo (Table V). Patients reported by 
Lemmer and associates differed slightly from the 
current study by having coronary artery bypass graft- 
ing only (100% versus 80%), a higher incidence of 
aspirin therapy (62% ver.sus 46%), and slightly 
longer hypothermic bypass time (98 minutes versus 
80 minutes). These differences probably account for 
the slightly higher blood loss in the study of Lemmer 
and associates. 3~ However, the efficacy of treatments 
(more accurate and precise heparin and protamine 
dosing versus aprotinin) in the face of hypothermic 
CPB, aspirin therapy, and lack of fresh autologous 
transfusion is remarkably similar in reducing blood 
loss and transfusion requirements. The refinement 
of a basic element of CPB, anticoagulation and 
reversal, with patient-specific dosing strategy, 
should be established first as the background for the 
evaluation of drugs and techniques intended to 
improve hemostasis. 
Cost. The cost of the drugs and tests as described 
in the test group is estimated to add $50 to $60 to 
the procedure if Hemochron coagulation timers are 
already available. The cost is more than offset by the 
reduced transfusion needs associated with de- 
creased bleeding and is approximately 5% to 10% of 
the estimated cost of aprotinin therapy in similar 
patients. ' 
We thank Drs. Susan Nicolson and Norig Ellison for 
editorial advice and Joan Aster and Jeff Gilfor for assis- 
tance in preparing the manuscript. 
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